Overview
Paris, May 31, 2022 – McDermott Will & Emery advised GeNeuro (Euronext Paris), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, on its €7, 7 million capital increase with cancellation of the preferential subscription rights which closed on May 16, 2022. The transaction consisted of an international private placement to certain qualified and institutional investors only of 2,678,251 new ordinary bearer shares of GeNeuro.
The Company intends to use the net proceeds of the Offering to complete the funding for its planned post-COVID trial with temelimab, complementing the grant received for this trial from the Swiss Federal Office for Public Health (FOPH).
The McDermott team that advised GeNeuro was led by David Revcolevschi, Partner and comprised Selim Laroussi on capital capital markets aspects and Côme de Saint-Vincent (Counsel) on tax aspects.
GeNeuro’s Swiss counsel was Gantey.
Bryan, Garnier & Co and Bryan Garniers Securities acted together as sole global coordinator and bookrunner of the offering.
